ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/API/(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
C34H38N8O9
702.7 g/mol
APIDanger

LHRH (1-5) (free acid)

CAS52434-75-0
Category
API
Compound Class
Peptide
Primary Use
Pharmaceutical Raw Material

LHRH (1-5) (free acid) is a peptide fragment corresponding to the N-terminal pentapeptide sequence of luteinizing hormone-releasing hormone. It is used as a pharmaceutical intermediate in the manufacture of peptide-based active pharmaceutical ingredients.

pharmaceutical intermediate for peptide synthesisresearch compound for gonadotropin-releasing hormone studies

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing LHRH (1-5) (free acid)?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

ReferenceSame Category

Dalareline

CAS52435-06-0

pharmaceutical raw material

ReferenceSame Category

(5alpha)-4,5-Epoxy-3,14-dihydroxymorphinan-6-one hydrochloride

CAS52446-24-9

pharmaceutical raw material

ReferenceSame Category

Flunarizine

CAS52468-60-7

pharmaceutical raw material

ReferenceSame Category

Buprenorphine

CAS52485-79-7

pharmaceutical raw material

Referencesame scaffold

Gonadorelin acetate impurity C

CAS37783-53-2

pharmaceutical raw material

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more

Safety Reference

Health Hazard
Health Hazard
Danger
H360May damage fertility or the unborn child
Identifiers
IUPAC Name

(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid

InChIKey

VVBDLEHCIKUJSA-XLIKFSOKSA-N

SMILES

C1CC(=O)N[C@@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O

Synonyms (6)
  • LHRH (1-5) (free acid)
  • pGlu-His-Trp-Ser-Tyr

Sourcing LHRH (1-5) (free acid)?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→